What is the current valuation of the plasma fractionation market in South Korea?

The market valuation was $954.6 Million in 2024. Read More

What is the projected market size for plasma fractionation in South Korea by 2035?

The projected valuation for 2035 is $2015.8 Million. Read More

What is the expected CAGR for the South Korea plasma fractionation market during 2025 - 2035?

The expected CAGR during this period is 7.03%. Read More

Which companies are the key players in the South Korea plasma fractionation market?

Key players include Grifols, CSL Behring, Takeda Pharmaceutical Company, and Octapharma. Read More

What are the main application segments in the South Korea plasma fractionation market?

Main application segments include Neurology, Hematology, General Medicine, and Immunology. Read More

What was the market valuation for the Immunology segment in 2024?

The Immunology segment was valued at $381.84 Million in 2024. Read More

How much is the Albumin product type projected to generate by 2035?

The Albumin product type is projected to generate $550.0 Million by 2035. Read More

What is the market size for hospitals as an end user in 2024?

In 2024, hospitals accounted for a market size of $300.0 Million. Read More

Which technology segment had a valuation of $300.0 Million in 2024?

The Chromatography technology segment had a valuation of $300.0 Million in 2024. Read More

What is the projected growth for the Coagulation Factors product type by 2035?

The Coagulation Factors product type is projected to grow to $400.0 Million by 2035. Read More

South Korea Plasma Fractionation Market

ID: MRFR/HC/47613-HCR

200 Pages

Vikita Thakur

Last Updated: April 06, 2026

South Korea Plasma Fractionation Market Research Report By Product Type (Immunoglobulin, Albumin, Coagulation Factors, Protease Inhibitors), By Application (Neurology, Hematology, General Medicine, Immunology), By End User (Hospitals, Ambulatory Surgical Centers, Blood Banks, Pharmaceutical Companies) and By Technology (Centrifugation, Chromatography, Precipitation, Filtration) -Forecast to 2035

South Korea Plasma Fractionation Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Pharmaceutical, BY Application (USD Million)
  1. 4.1.1 Neurology
  2. 4.1.2 Hematology
  3. 4.1.3 General Medicine
  4. 4.1.4 Immunology
2. 4.2 Pharmaceutical, BY Product Type (USD Million)
  1. 4.2.1 Immunoglobulin
  2. 4.2.2 Albumin
  3. 4.2.3 Coagulation Factors
  4. 4.2.4 Protease Inhibitors
3. 4.3 Pharmaceutical, BY End User (USD Million)
  1. 4.3.1 Hospitals
  2. 4.3.2 Ambulatory Surgical Centers
  3. 4.3.3 Blood Banks
  4. 4.3.4 Pharmaceutical Companies
4. 4.4 Pharmaceutical, BY Technology (USD Million)
  1. 4.4.1 Centrifugation
  2. 4.4.2 Chromatography
  3. 4.4.3 Precipitation
  4. 4.4.4 Filtration
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Pharmaceutical
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Grifols (ES)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 CSL Behring (AU)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Takeda Pharmaceutical Company (JP)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Octapharma (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Kedrion (IT)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Biotest AG (DE)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 LFB Group (FR)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Sangamo Therapeutics (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Emergent BioSolutions (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
3. 6.3 SOUTH KOREA MARKET ANALYSIS BY PRODUCT TYPE
4. 6.4 SOUTH KOREA MARKET ANALYSIS BY END USER
5. 6.5 SOUTH KOREA MARKET ANALYSIS BY TECHNOLOGY
6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
12. 6.12 PHARMACEUTICAL, BY APPLICATION, 2024 (% SHARE)
13. 6.13 PHARMACEUTICAL, BY APPLICATION, 2024 TO 2035 (USD Million)
14. 6.14 PHARMACEUTICAL, BY PRODUCT TYPE, 2024 (% SHARE)
15. 6.15 PHARMACEUTICAL, BY PRODUCT TYPE, 2024 TO 2035 (USD Million)
16. 6.16 PHARMACEUTICAL, BY END USER, 2024 (% SHARE)
17. 6.17 PHARMACEUTICAL, BY END USER, 2024 TO 2035 (USD Million)
18. 6.18 PHARMACEUTICAL, BY TECHNOLOGY, 2024 (% SHARE)
19. 6.19 PHARMACEUTICAL, BY TECHNOLOGY, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.2.2 BY PRODUCT TYPE, 2025-2035 (USD Million)
  3. 7.2.3 BY END USER, 2025-2035 (USD Million)
  4. 7.2.4 BY TECHNOLOGY, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

South Korea Pharmaceutical Market Segmentation

Pharmaceutical By Application (USD Million, 2025-2035)

Neurology
Hematology
General Medicine
Immunology

Pharmaceutical By Product Type (USD Million, 2025-2035)

Immunoglobulin
Albumin
Coagulation Factors
Protease Inhibitors

Pharmaceutical By End User (USD Million, 2025-2035)

Hospitals
Ambulatory Surgical Centers
Blood Banks
Pharmaceutical Companies

Pharmaceutical By Technology (USD Million, 2025-2035)

Centrifugation
Chromatography
Precipitation
Filtration

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”